

**Dr. Norbert W. Bischofberger**, Hillsborough, California, USA

born January 10, 1956, in Mellau, Austria

Austrian and US citizen



President and Chief Executive Officer at Kronos Bio, Inc.

- 1975 – 1980 Studies of chemistry at Leopold-Franzens-University, Innsbruck, Austria
- 1980 – 1983 Doctorate (Dr. rer. nat.) at the Eidgenössische Technische Hochschule Zurich, Switzerland
- 1983 – 1984 Postdoc at Syntex, Inc., Palo Alto, California, USA
- 1984 – 1986 Postdoc at Harvard University, Cambridge, Massachusetts, USA
- 1986 – 1990 Scientist in the Molecular Biology Department at Genentech Inc., South San Francisco, California, USA, from 1988 Manager DNA Synthesis
- 1990 – 2018 Gilead Sciences Inc., Foster City, California, USA
- 1990 – 1993 Director Organic Chemistry
- 1993 – 1995 Vice President Organic Chemistry
- 1995 – 1997 Vice President Research
- 1997 – 1999 Senior Vice President Research
- 1999 – 2007 Senior Vice President Research and Development
- 2007 – 2018 Executive Vice President Research and Development and Chief Scientific Officer
- since 2018 President and Chief Executive Officer at Kronos Bio, Inc., San Mateo, California, USA

Membership of statutory supervisory boards:

- Bayer Aktiengesellschaft (since 2017, listed)

Membership of comparable supervisory bodies of corporations in Germany or abroad:

- Member of the Board of Directors (non-executive) of Morphic Holding, Inc., Waltham, Massachusetts, USA (since 2019, listed)

Membership in committees of the Supervisory Board of Bayer Aktiengesellschaft:

- Innovation Committee

Dr. Bischofberger does not perform other significant activities.

In addition to his international business experience, Dr. Bischofberger supports the work of the Supervisory Board in particular through the expertise and experience he possesses in the fields of pharmaceuticals and research and development.

The Supervisory Board has satisfied itself that Dr. Bischofberger is able to meet the expected time commitment for performing his Supervisory Board duties. Particularly, the time required for his non-executive membership in the Board of Directors of Morphic Holding, Inc., is limited and additional travel is not necessary. In 2021, Dr. Bischofberger attended all meetings of the Supervisory Board and of the committee of the Supervisory Board of which he is a member.

Dr. Bischofberger has been a member of the Company's Supervisory Board since 2017 (i.e. for one term). The Supervisory Board considers Dr. Bischofberger to be independent. Beyond the membership of Dr. Bischofberger on the Company's Supervisory Board, the Supervisory Board does not consider there to be any personal or business relationships between Dr. Bischofberger on the one hand and the companies of the Bayer Group, the governance bodies of Bayer Aktiengesellschaft, or any stockholder that directly or indirectly holds more than 10 percent of the voting shares of Bayer Aktiengesellschaft on the other, that are of material significance to the decision of the Stockholders' Meeting regarding his election.